Citations 1
CSF cytokine, chemokine and injury biomarker profile of glial fibrillary acidic protein (GFAP) autoimmunity
Segal, Yahel , Mangioris, Georgios , Lennon, Vanda A. , Yang, Binxia , Dubey, Divyanshu , McKeon, Andrew , Mills, John R. , Tolédano, Michel B. , Vodopivec, Ivana, Pittock, Sean J. , Ζεκερίδου, Αναστασία , Dubey, Divyanshu , Pittock, S J , Lennon, Vanda, McKeon, Andrew , Zekeridou, Anastasia , Dubey, Divyanshu , Yang, Binxia , Flanagan, Eoin P. , Toledano, Michel
Annals of Clinical and Translational Neurology | January 27, 2025 | Volume: 12 | Issue: 4 | Pages: 855-860
AbstractDefining the CSF cytokine/chemokine and injury biomarker signature of glial fibrillary acidic protein (GFAP) autoimmunity can inform immunopathogenesis. CSF GFAP‐IgG‐positive samples (N = 98) were tested for 17 cytokines/chemokines, neurofilament light chain (NfL), and GFAP (ELLA, Bio‐Techne). Controls included non‐inflammatory (N = 42), AQP4‐IgG‐positive (N = 83), CNS infections (N = 13), and neurosarcoidosis (N = 32). IL5, IL6, IL10, IL8/CXCL8, CXCL9, CXCL10, CXCL13, BAFF, GM‐CSF, IFN‐gamma, and TNF‐alpha concentrations were higher compared to non‐inflammatory controls (P < 0.01). GFAP concentrations were similar to those of AQP4‐IgG‐positive patients; NfL was higher (P < 0.001) and correlated with MRI changes and outcomes. CSF cytokine/chemokine findings in GFAP autoimmunity correlate with histopathology; GFAP and NfL hold promise as disease biomarkers.